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SUMMARY 
The main pathological feature of Parkinson’s disease (PD) is the formation of Lewy 
bodies in the substantia nigra (SN). Alpha synuclein (-syn) misfolds and aggregates 
into insoluble amorphous or fibrillar amyloid-like assemblies, which is the core 
component of Lewy bodies. -syn aggregation is implicated in altered synaptic function 
and ultimately results in synaptic loss and even neuronal death. MicroRNAs (miRNAs) 
are defined as crucial part of our genome and are involved in various cellular processes, 
such as neuronal cell death, synaptic dysfunction and inflammatory response. 
Recently, a differential expression of miRNAs has been found in PD patients’ brains. 
However, the pathophysiological relevance of these findings is still not understood, 
and require to be analyzed in animal models of PD. In order to shed light on the role 
of miRNAs for synaptic loss in PD, miRNA sequencing was performed in PDGF-hum-
syn transgenic mouse that show synaptic loss already at 3 months of age. The 
differential expression of miRNAs was studied prior to the loss of synapses at 2 months 
of age and in an age when spine loss has been documented at 3 and 4 months of age. 
Very few miRNAs changes were observed between 3 and 4 months old PDGF mice. 
However, when 3- and 4-month-old PDGF mice were compared to 2-month-old mice, 
several differential expressed mi-RNAs were observed including mir-184-3p, mir-182-
5p, mir-34c-5p and mir-200b-3p. These miRNAs changes might contribute to early 
synaptic loss that occurs between the 2 and 3 months in young PDGF mice.  
Collectively, this dissertation shows for the first time a correlation of the expression of 
miRNAs mir-184-3p, mir-182-5p, mir-34c-5p and mir-200b-3p with dendritic spine loss 
in a PD mouse model.   
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ZUSAMMENFASSUNG 
Das pathologische Hauptmerkmal der Parkinson-Krankheit (PD) ist der Nachweiß von 
Lewy-Körpern in der Substantia nigra (SN). Alpha-Synuclein (-syn) faltet sich 
fehlerhaft und aggregiert zu unlöslichen amorphen oder fibrillären Amyloid-ähnlichen 
Aggregaten, welche der Kernbestandteil der Lewy-Körper und Lewy Neuriten sind. 
Darüber hinaus geht man davon aus, dass die -syn-Aggregation die synaptische 
Funktion beeinträchtigt und zu einem Verlust von Synapsen und dem Untergang von 
Nervenzellen führt. MicroRNAs (miRNAs) sind definiert als wesentlicher Bestandteil 
unseres Genoms und sind an verschiedenen zellulären Prozessen beteiligt, wie z. B. 
dem Absterben von Nervenzellen, synaptischen Dysfunktionen und 
Entzündungsreaktionen. Vor kurzem wurde eine differentielle Expression von miRNAs 
im Gehirn von PD-Patienten beschrieben. Allerdings ist die pathophysiologische 
Relevanz dieser Befunde noch nicht verstanden und erfordert die Untersuchung von 
Tiermodellen der PD. Um die Rolle von miRNAs bei dem Verlust von Synapsen in PD 
aufzuklären, wurde miRNA-Sequenzierung bei transgenen PDGF-hum-syn-Mäusen 
durchgeführt, welche bereits im Alter von 3 Monaten einen Verlust der Synapsen 
aufwiesen. Die differentielle Expression von miRNAs wurde vor dem Verlust von 
Synapsen im Alter von 2 Monaten untersucht, sowie in einem Alter, in dem ein Verlust 
der Dornenfortsätze im Alter von 3 und 4 Monaten dokumentiert wurde. Es wurden 
sehr wenige Veränderungen der miRNAs zwischen 3 und 4 Monate alten PDGF-
Mäusen beobachtet. Jedoch wurden beim Vergleich von 3 und 4 Monate alten PDGF-
Mäusen mit 2 Monate alten Mäusen mehrere differentiell exprimierte miRNAs 
gefunden, einschließlich mir-184-3p, mir-182-5p, mir-34c-5p und mir-200b-3p. Diese 
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Veränderungen der miRNAs könnten zu einem frühen synaptischen Verlust beitragen, 
welcher zwischen 2 und 3 Monaten bei jungen PDGF-Mäusen auftritt. 
Zusammenfassend zeigt diese Dissertation zum ersten Mal eine Korrelation der 
Expression der miRNAs mir-184-3p, mir-182-5p, mir-34c-5p und mir-200b-3p mit dem 
Verlust der dendritischen Dornenfortsätze in einem PD-Mausmodell.  
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INTRODUCTION 
1. Parkinson’s disease 
PD is the most common neurodegenerative movement disorder worldwide. Over 7 
million people are affected (Sherer, 2011). The main features of PD are bradykinesia, 
impaired posture and balance, muscle rigidity and tremor (Aron et al., 2010). 
Pathological hallmarks of PD are the progressive loss of dopaminergic (DA) neurons 
in the substantia nigra pars compacta (SNpc), the formation of Lewy bodies by the 
accumulation of alpha-synuclein (-syn) (Leggio et al., 2017). The underlying 
mechanisms of PD have been partially illustrated in recent years. It was demonstrated 
that a mutation in VPS35 cause to late-onset PD (Zimprich et al., 2011). Mutations in 
leucine rich repeat kinase 2 (LRRK2) have been confirmed to result in familial PD (Liu 
et al., 2012). Furthermore, microRNAs (miRNAs) are also considered to be involved in 
the progression of PD. 
2. Cognition impairment of Parkinson’s disease 
Cognitive impairment, including dementia (Parkinson’s disease dementia, PDD), is a 
common characteristic in PD patients. In PDD, the onset of dementia is usually several 
years after the PD diagnosis. Propagation of -syn aggregates to the neocortical 
regions according to the Braak-PD staging (Figure 1) is the main substrate of cognitive 
decline in PDD (Emre et al., 2007). 
 10 
Fig. 1: The Braak staging system of PD 
There are 6 stages by pathological classification in PD. The -syn pathology spreads from the 
olfactory bulb and medulla oblongata, pass the limbic system to the neocortex. The red shading 
displays the pattern of pathology. (From Doty, 2012) 
It has widely been accepted that memory formation is linked to synaptic plasticity, 
which is the alters in the strength of the synaptic connections between neurons. 
Synaptic dysregulation in the hippocampus and association cortices are considered as 
an early characteristic and related to the severity of cognitive decline in Alzheimer 
disease (AD) (DeKosky et al., 1996). It was also reported that the PD patients carried 
the mutation of glucocerebrosidase gene show lower nigrostriatal dopamine 
transporter density and reduced synaptic activity in parietal and posterior cortices (Cilia 
et al.,2016). 
2. Alpha-synuclein 
Alpha-synuclein (-syn), a small (14 kDa) cytosolic protein, is the main component of 
Lewy bodies. It contains 3 sections: an amphipathic N-terminal domain which interacts 
with lipid membranes, an acidic C terminal region function on the suppression of 
aggregation, and a central hydrophobic core related to protein aggregation (Snead et 
al., 2014). 
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Under physiological conditions, -syn, a natively unfolded monomer in the cytoplasm, 
is involved in the clustering of synaptic vesicles (Burré et al., 2010; Maroteaux et al., 
1988), whereas under pathological conditions, -syn is misfolded into pathogenic 
species (dimers, trimers and oligomers) which ultimately hamper synaptic function and 
cause neuronal death (Calo et al.,2016) (Figure 2). 
Fig. 2: Hypothetical model of -syn toxicity and spread of pathology in PD 
Misfolded proteins aggregate into higher-order structures which contains protofibrils, other 
intermediates and amyloid fibrils, they are the pathological foundational composition of -syn, and 
eventually form Lewy bodies. Chaperones, ubiquitin proteasomes and phagosome-lysosome 
systems, also called normal quality-control systems, function on avoiding protein misfolding or 
removing misfolded proteins, however, oligomeric species of -syn could cause to the dysfunction 
of this system. (Kingwell, 2017) 
Recent data confirm that the progression of PD may be implicated to the cell-to-cell 
spread of pathological structures of -syn. The transmission of -syn is considered to 
have various toxic consequences, including oxidative stress, protein sequestration, 
disruption of axonal transport, synaptic dysfunction, inhibition of UPS and 
mitochondrial dysfunction. 
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In the brain, -syn is found mainly in presynaptic terminals of neurons. Presynaptic 
terminals release neurotransmitters from synaptic vesicles. Normal brain functions via 
the release of neurotransmitters transfers signals between neurons. Although the 
function of -syn is not well understood, it was confirmed that -syn plays an important 
role in maintaining a sufficient supply of synaptic vesicles in presynaptic terminals. It 
may benefit to mediate the dopaminergic release, which is a neurotransmitter and 
important for the controlling of starting or stopping movements.  
3. MicroRNAs 
MicroRNAs (Figure 3) were first described in 1993 (Lee et al., 1993). They are a class 
of 21-25 nucleotides (nt) long, non-coding and single-stranded RNA that regulate the 
expression of genes (Kabiri Rad et al., 2018; Boese et al., 2016; Doeppner et al., 2013; 
Chédotal, 2011). The miRNAs are demonstrated to be implicated in various stages of 
growth, development, and differentiation of the cells (Jan Christoph Koch et al., 2012), 
and enriched and active in the brain (Meza-Sosa et al., 2014).  
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Fig. 3: miRNA biogenesis pathway and function 
First, a primary transcript (pri-miRNA) is generated from the miRNA gene by the RNA polymerase 
II. Then, Drosha complex and DiGeorge syndrome chromosomal region-8 cleaved the pri-miRNA 
into precursor miRNAs, which is 70 nucleotides stem-loop transcripts. Then, pre-miRNA is 
transported to the cytoplasm by exportin 5. After that, double-strand miRNA is generated by the 
cleavage of Endoribonuclease III Dicer. After denaturing by helicase, mature miRNA is generated 
from one single-strand, another strand degrades. At last, the mature miRNA interacts with the RNA-
induced silencing complex in two different pathways, which results in the modulation of the mRNA 
gene expression. (Khodadadian et al., 2018) 
The role of miRNAs in PD pathogenesis is still unclear, however a few studies in PD 
patients and animal models were performed, in which miRNAs were identified as 
powerful regulators of physiological and pathological cellular processes (Sayed et al., 
2011). The increase of mir-184 was confirmed to attenuated pathogenic leucine-rich 
repeat kinase 2 (LRRK2, its mutations were proofed to result in PD) effects in 
Drosophila (Gehrke et al., 2010). Mir-7 was reported to repress -syn expression, and 
to facilitate the degradation of pre-formed fibrils of -syn (Choi et al., 2018). Mir-132 
was considered to involve in maintaining of synaptic plasticity for memory function 
(Nadim et al., 2017), the repression of mir-132 was demonstrated to affect the 
maturation of dendritic spines in vivo (Mellios, 2011). More and more miRNAs are 
considered to play an important role in PD pathogenesis (Lewis, 2014; Kim et al., 2007). 
The study of the role of miRNAs in PD is therefore a novel approach to understanding 
PD pathogenesis. 
4. PD mouse models  
Some studies demonstrated that the differential expression of miRNAs exist in PD 
patients’ brain (Hoss et al., 2016), implying that these miRNAs play a role in PD 
pathogenesis. However, to do functional research on miRNAs in humans is difficult 
and animal models are useful tools in PD translational research.  
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Numerous lines of mice overexpressing normal α-syn or α-syn with pathogenic 
mutations (e.g. A53T, A30P) have been generated using distinct promoters (e.g. Thy-
1, PDGF-β) and transgenes (Fernagut et al., 2004). The main advantage of -syn 
models is that -syn positive inclusions could be replicated, although the typical Lewy 
bodies in human PD is not found in murine (Maries et al., 2003). Reduced olfaction, 
autonomic dysfunction, -syn accumulation and motor deficits are the features of mice 
with overexpressing wild-type human -syn, however, the model is lack of nigrostriatal 
neurodegeneration (Rockenstein et al., 2002; Fleming et al., 2004; Chesselet et al., 
2008; Fleming et al., 2008).  
PDGF-hum-syn transgenic mouse model was used for the study in this dissertation. 
These mice overexpress human -syn under the control of the human PDGF-
 promoter. -syn is strongest expressed in the neocortex, hippocampus, olfactory 
bulb, and limbic system, and accumulated starting at 3 months of age (Amschl et al., 
2013; Masliah et al., 2000). It was reported that synaptic loss starts from 3 months of 
age in the neocortex of PDGF mice (Blumenstock et al., 2017). 
5. Aim of the study 
In order to identify miRNAs changes directly and possibly causally related to synaptic 
plasticity in the young PDGF mice, miRNA sequencing was performed in 2-, 3- and 4-
months old animals. MiRNA sequencing was performed applying next-generation 
sequencing to sequence all miRNAs in a given sample in order to discover miRNAs 
changes that coincide with the loss of synapses.   
 15 
MATERIAL AND METHODS 
1. Animals 
 PDGF-hum--syn mice were supported from QPS Austria Neuropharmacology 
(Grambach, Austria) and bred on a C57Bl/6 background. All mice were kept under 
pathogen-free conditions in the animal facility of the ZNP (Center for Neuropathology 
and Prion Research) of the LMU (Ludwig-Maximilians-University of Munich). All mice 
were housed in groups (maximum of 5 mice per cage) with food and water provided 
ad libitum and kept on a 12h light/ dark cycle, the room temperature maintained at 21 
± 1°C. The body weight and health state were checked every day. All experiments 
were approved by the Bavarian government (Az. 55.2-1-54-2532-163-13) and 
performed according to the animal protection law. The mice used in these experiments 
are listed in Table 1.  
* M and F represent male and female. 
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2. Genotyping 
In order to determine the genotypes of all mice, polymerase chain reaction (PCR) was 
performed. The Invisorb® DNA Tissue HTS 96 Kit (Invitek molecular) was used for 
DNA extraction. In brief, 20mg mouse tissue was used to isolate DNA, it was incubated 
with 400 μl of Lysis Buffer G overnight at 52°C, then the mixture was centrifuged for 
10 min at 1700 g. The supernatant was transferred into a new collection tube and 
mixed with 200 μl Binding Buffer A, then the mixture was centrifuged for 5 min at 1700 
g. After discarding the supernatant, 550 μl Washing Buffer was added into the pellet, 
followed twice by 5 min centrifugation at 1700 g. Lastly, the DNA extraction was 
obtained after washing with 100 μl of prewarmed (52°C) Elution Buffer.   
 PCR was performed with the extracted DNA to identify the genotype of mice. The 
primer 209F (CTGGSSGSTATGCCTGTGGA) with 20 bp length and 50R 
(CATCAATGTATCTTATCATGTCTGGATTCT) with 29 bp length were used in this 
study. The reagents for PCR reaction was listed in Table 2, the PCR program was 
listed in Table 3. Then the PCR products were loaded on a 1.0% agarose gel, and 
analyzed by gel electrophoresis (120-195 V, 60-90 min). After that, post-staining was 
performed with SYBR® gold nucleic acid gel stain for 5 min. Finally, a photograph of 
the gel was taken under UV light source.  
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3. Total RNA and small RNA isolation 
Total RNA or small RNA was isolated by using a Qiagen® miRNeasy Micro Kit (No. 
217084). In brief, 5 mg murine cortical tissue was thoroughly homogenized with 700 μl 
QIAzol Lysis Reagent in a collection tube by using a plastic pestle, then placed it at RT 
for 5 min. Next, the homogenate was incubated at RT for 2-3 min after mixing with 140 
μl chloroform, followed by 12000 g centrifugation at 4°C for 15 min (Eppendorf, 
Centrifuge 5804R). Then, the total RNA isolation or small RNA isolation was 
correspondingly performed following the steps in 3.1 or 3.2. 
3.1 Total RNA isolation 
The supernatant of homogenate was transferred to a new tube, vortexed for 10 sec 
after adding 525 μl of 100% ethanol (total volume: 900 μl). 700 μl of the mixture was 
pipetted into an RNeasy MinElute spin column in a 2 ml collection tube, followed by 
8000 g centrifugation for 15 sec at room temperature (RT), then the flow-through was 
discarded (this step would be repeated with the remaining mixture). After that, 700 μl 
Buffer RWT was added into the column, followed by 8000 g centrifugation for 15 sec. 
After that, 500 μl of 80 % ethanol was pipetted into the column, followed by 8000 g 
centrifugation for 2 min. Then the flow-through was discarded. In order to dry the 
membrane of the column, centrifugation was performed for the column in a new tube 
 18 
for 5 min at full speed, then the flow-through was discarded. Lastly, 14 μl of RNase-
free water was added into the column in a new 1.5 ml tube, after centrifuging at full 
speed for 1 min, the total RNA was collected in the tube.  
3.2 Small RNA isolation 
The supernatant of homogenate was transferred to a new tube and mixed with 350 μl 
of 70 % ethanol. 700 μl of the mixture was pipetted into an RNeasy MinElute spin 
column in a 2 ml collection tube, followed by 8000 g centrifugation at RT for 15 sec, 
the flow-through containing the small RNA was kept. Then the flow-through was mixed 
with 450 μl of 100% ethanol, the total volume of the mixture was approximately 1150 
μl. 700 μl of the mixture was pipetted into a new RNeasy MinElute spin column in a 
new 2 ml tube, followed by 8000 g centrifugation at RT for 15 sec, the flow-through 
was discarded (this step would be repeated with the remaining mixture). Next, 700 μl 
of Buffer RWT was pipetted to the column, then centrifuged the column at 8000 g for 
15 sec, the column was kept. Then 500 μl of Buffer RPE was pipetted to the column 
followed by 8000 g centrifugation for 15 sec. After that, 500 μl of 80 % ethanol was 
added to the column, then centrifuged at 8000 g for 2 min, then the membrane of 
column was dried by 8000 g centrifugation for 5 min. Lastly, 14 μl RNase-free water 
was added into the column in a new tube, after centrifuging at 8000 g for 1 min, the 
small RNA was collected in the tube. 
4. Concentration measurement of double strand DNA (ds DNA) 
Qubit 3.0 Fluorometer (Invitrogen™, Q33216) and Qubit™ dsDNA HS Assay Kit 
(Thermo Fisher, Q32851) were used for concentration measurement of dsDNA. In brief, 
the working solution was prepared by diluting the dsDNA HS Reagent 1:200 in dsDNA 
HS Buffer. 190 µl of working solution and 10 µl of standard reagent 1 (or 2) were mixed 
in the tube used for standard 1 (or 2). Then 199 µl of working solution and 1 µl of a 
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sample was mixed in a new tube. After incubation at RT for 2 min, the standard tubes 
were inserted into the sample chamber of Qubit 3.0 Fluorometer, and the concentration 
of the standards was read by running dsDNA system. Followed by running with sample 
tubes, the concentration was read out and saved as documentation. 
5. Western blot 
20 mg of murine cortical tissue was used for western blot analysis to identify the 
expression of -syn protein in PDGF mice. 200 μl of homogenate buffer (the 
formulation was listed in Table 4) was mixed with the tissue in a 1.5 ml collection tube, 
then the mixture was homogenized by using a plastic homogenizer on ice. After that, 
the total protein in each sample was quantitated by using the Bicinchoninic Acid protein 
assay (BCA protein assay, Smith et al., 1985). 20 and 50 µg of protein for each sample 
was added to 2 lanes of 12.5% SDS-PAGE gel (the formulation was listed in Table 5), 
respectively. Then the protein migration was driven by electrophoresis in running buffer 
(the formulation was listed in Table 6) at 80 V for 20 min, followed by electrophoresis 
at 120 V for 40 min. Next, the protein was transferred to the PVDF membrane by using 
semi dry blotting for 2 h (the formulation of transfer buffer was listed in Table 7). This 
was followed by membrane incubation in PBS with 4% PFA and 0.01% Glutaraldehyde 
for 30 min at RT and then the membrane was washed with 1 × TBST for 5 × 4 min. 
Next, the membrane was placed in Ponceau dye (0.2% Ponceau S, 3% acetic acid) 
for 5 min to stain for total protein. After washing the membrane with deionized water to 
remove the excessive Ponceau dye, the membrane with protein bands was scanned 
for saving as documentation. Following incubation in 5% TBST-milk for 1 h, the 
membrane was placed in 50 ml of 5% TBST-milk including 5 µl of -syn antibody 4B12 
(ThermoFisher scientific, #MA1-90346) at 4°C overnight. Then the membrane was 
washed with 1 × TBST for 3 × 5 min and incubated, followed by incubation in 25 ml of 
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5% TBST-milk included 5 µl of anti-Mouse-HRP secondary antibody (Cell Signaling 
Technology, #7076) at RT for 1 h. Then the membrane was washed by 1 × TBST for 
3 × 5 min, followed by incubation with 2 ml of ECL solution at RT for 2-3 min. Finally, 
the protein bands on the membrane were detected by using Chemostar ECL and 
Fluorescence Imager (Intas science imaging). 
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6. MiRNA sequencing 
The miRNA sequencing (Figure 4) was performed to identify the miRNAs abundance 
and differential expression by using Illumina® NextSeq 550 System.  
Fig. 4: The workflow of miRNA sequencing 
Firstly, the total RNA or small RNA isolated from a sample is used for miRNA sequencing. Secondly, 
the adaptors are ligated to total RNA or small RNA. Thirdly, reverse transcription and amplification 
of the products are performed to get the cDNA. Next, a gel purification to fractionate the cDNA 
fragments with specific sizes (145-160 bp) which corresponded to miRNAs length (22-25 nt) plus 
adaptors has to be performed. Lastly, miRNA sequencing is performed with a sequencer.  
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6.1 Adapters Ligation 
5 μl of a sample including 50 ng of small RNA was incubated with 1 μl of RNA 3’ 
Adaptor at 70°C for 2 min. Then the sample was incubated with 2 μl of Ligation Buffer, 
1 μl of RNase Inhibitor and 1 μl of T4 RNA Ligase 2 (Deletion Mutant. Biozym, 138031) 
at 28°C for 1 h. After that, the sample was incubated with 1 μl of Stop Solution at 28°C 
for 15 min, the products named RNA 3’ Adaptor mixture. At the meanwhile, a new PCR 
tube with 1 μl of RNA 5’ Adaptor was incubated at 70°C for 2 min, then the RNA 5’ 
Adaptor together with 1 μl of ATP and 1 μl of T4 RNA Ligase were added to the RNA 
3’ Adaptor mixture and the mixture was incubated at 28°C for 1 h. The total volume of 
the mixture named adapter-ligated RNA library was 14 μl. 
6.2 cDNA template preparation (Reverse Transcription and PCR) 
6 μl of the adapter-ligated RNA library was incubated with 1 μl of RNA Reverse 
Transcription Primer in a new tube at 70°C for 2 min. Then the products were incubated 
with 2 μl of First Strand Buffer, 0.5 μl of dNTP Mix (12.5mM), 1 μl of DTT, 1 μl of RNase 
Inhibitor and 1 μl of SuperScript II Reverse Transcriptase (Invitrogen™, 18064014) at 
50°C for 1 h. After that, 8.5 μl of Ultrapure water, 25 μl of PCR Mix, 2 μl of RNA PCR 
Primer and 2 μl of Index were added to the sample and underwent PCR with the 
program listed in Table 8. 
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6.3 Quality control of the samples 
The size and concentration of cDNA was checked with a High Sensitivity DNA chip 
(Agilent, 5067-4626) by using Agilent Bioanalyzer 2100. In brief, 15 μl of High 
Sensitivity DNA dye concentrate was mixed with 300 μl of High Sensitivity DNA gel 
matrix after incubation at RT for 30 min, followed by 2240 g centrifugation for 15 min. 
Then a High Sensitivity DNA chip was placed on the priming station. 9 μl of gel-dye 
was added in the well which was marked with , followed by closing the chip priming 
station, and pressing the plunger from 1 ml to the bottom until it was held by clip. 1 min 
later, the clip was released. Next, 9 μl of gel-dye was added in the wells which was 
marked with G, 5 μl of marker was added in all sample and ladder wells. Then 1 μl of 
ladder was pipetted in the ladder well, and 1 μl of each sample was added in the 
corresponding sample well. After 2400 rpm vortexing for 1 min, the chip was placed on 
the Agilent bioanalyzer 2100. The following figure 5 shows typical results from human 
brain total RNA. 
Fig. 5: Sample trace of amplicons on a High Sensitivity DNA Chip 
The x axis shows the timeline (also can be changed to size scale), the y axis shows fluorescence 
absorption intensity. The first and last peaks were the lower and upper marker peaks. The other 
peaks represent the cDNA fragments with different sizes, respectively. The yellow arrows point out 
the mature miRNAs and other regulatory small RNAs. 
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6.4 Size Fractionation (gel purification of cDNA) 
Since the size of miRNAs was 22-25 nt, the length of corresponding cDNA would be 
145-160 bp (the length of adaptors was around 130 nt), thus the cDNA fragments with 
145-160 bp length had to be purified.  
Firstly, all the samples were pooled together in equimolar amounts based on the 
concentration measured by Qubit™. Secondly, the gel purification was performed with 
8% native PAGE gel (Figure 6, Illumina Document #15004197 v02). 2 μl of High-
Resolution Ladder was mixed with 2 μl DNA loading dye, then the mixture was loaded 
to the first and last lanes of gel in equal amounts as size ladders. Then 2 μl of Custom 
RNA Ladder was mixed with 2 μl DNA loading dye, the mixture was averagely loaded 
to the lanes closed to the High-Resolution Ladder as the controls. After that, 50 μl of 
the sample was mixed with 10 μl DNA loading dye, then the mixture was averagely 
loaded to 2 lanes between the Custom RNA Ladders. After that, DNA migration was 
driven by 80 V for 120 min until the blue front dye left the gel. 
Fig. 6: Gel purification for the cDNA template of miRNA 
shows the lanes loaded with the sample. shows the bands of miRNAs fragments between 
145 and 160 bp. presents the controls named Custom RNA Ladder. presents the size ladder 
named High-Resolution Ladder. 
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Thirdly, the gel was placed in 100 ml running buffer with 10 μl SYBR™ Gold Nucleic 
Acid Gel Stain (Invitrogen™, S11494) for 5 min, then the DNA bands could be seen 
under the blue light (Invitrogen™ E-Gel™ iBase™ and E-Gel™ Safe Imager™ Combo 
Kit, 10001123). The bands of the sample size between 145 and 160 bp were cut down 
and placed into a 0.5 ml gel breaker tube within a 2 ml collection tube, followed by 
20000 g centrifugation for 2 min to collect the gel debris. Then 200 μl of ultrapure water 
was added to the gel debris, followed by 500 rpm shaking for at least 2 h by using a 
Thermomixer to elute the DNA. Next, the debris was transferred to a 5 μm filter in a 2 
ml collection tube, followed by 600 g centrifugation for 10 sec, the flow-through was 
collected for further miRNA sequencing. The quality of the sample was checked with 
Bioanalyzer analysis, the concentration was also measured by using Qubit and 
normalized to 4 nM by using Resuspension Buffer (RSB) (Illumina, FC-110-3002). The 
formulation of converting ng/μl to nM for dsDNA is as follows: 
6.5 Denature and dilute the sample 
5 μl of the sample (4 nM) was mixed with 5 μl of 0.2 N NaOH, followed by 280 g 
centrifugation for 1 min, incubated it at RT for 5 min. Then 5 μl of Tris-HCl (200 mM, 
pH 7) was added to the sample, followed by 280 g centrifugation for 1 min. After that, 
985 μl of Hybridization buffer was added to the sample, followed by 280 g 
centrifugation for 1 min, thus the sample was diluted to 20 pM. Next, 117 μl of the 
sample (20 pM) was mixed with 1183 μl of Hybridization buffer, in order to dilute the 
sample to 1.8 pM, the total volume of was 1.3 ml. 
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6.6 Sequencing on the Illumina platform 
1.3 ml of the sample (1.8 pM) was loaded on the NextSeq 500/550 High Output Flow 
Cell Cartridge (75 Cycles. Illumina, No. 20024906), then the sequencing was 
performed on NextSeq 550 platform (Illumina, SY-415-1002). 
7. Data processing 
For miRNA sequencing data analysis, the Galaxy bioinformatics analysis platform was 
used for the assessment of the raw reads, the alignment of reads to the genome and 
the quantification of gene expression. Reads were counted per sample using the 
Rsubread package (Chen et al., 2016) and the miRNA annotation database version 22 
from miRbase (http://www.mirbase.org/). EdgeR package (Robinson et al., 2010) was 
used for differential expression analysis of miRNAs. P‐value was adjusted using q‐
value. And q‐value < 0.1 was set as the threshold for significantly differential 
expression by default. 
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RESULTS 
Based on that accumulation of -syn resulted in the decline of cortical spine density in 
young adult PDGF mice starting from 3 months of age (Blumenstock et al., 2017), a 
hypothesis came out that several miRNAs may mediate synaptic loss in young PDGF 
mice. In order to analyze the expression of miRNAs, miRNA sequencing was 
performed in cortical tissue of PDGF mice and controls at different time points (2-, 3- 
and 4- months). Information of mice age and gender that have been studied is listed in 
Table 9. 
* M and F represent male and female. * ID No. 714 mouse was excluded from further analysis (see 
Chapter 2.2.1 of Results). * ID No. 660 and 676 mice were also excluded from further analysis 
since -syn was not expressed in these PDGF mice (see Chapter 1 of Results). 
1. -syn expression identification in PDGF mice 
In all PDGF mice, a western blot analysis was performed in order to confirm the 
expression of the human -syn transgene. An -syn monoclonal antibody (4B12) was 
used as primary antibody, and anti-mouse IgG, HRP-linked antibody was used as 
secondary antibody to bind to the primary antibody. A band of 15-25 kDa was detected 
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which confirmed the expression of the human -syn transgene in these mice (Figure 
7A-C). 
Fig. 7: Expression of the human -syn transgene in PDGF mice 
12.5% SDS-PAGE gel was used for western blot analysis. Each sample was loaded on 2 lanes 
with the total protein amount of 20 and 50 µg respectively. Cortical tissue from PDGF mice at the 
age of 2 months (A), 3 months (B) and 4 months (C) were analyzed for the expression of the human 
-syn transgene. The bands which molecular weight between 15 and 25 kDa represent -syn 
protein. PDGF mice number: n=6 (2 months), n=5 (3 months), n=5 (4 months). 
The results showed that 1 out of 5 3-month-old PDGF mice did not express the -syn 
transgene, and also 1 out of 5 4-month-old PDGF mice did not express it. These 2 
mice (ID No. 676 and 660) were excluded from further analysis. 
2. Analysis of miRNA expression in PDGF mice  
In order to observe miRNAs changes at different time points in PDGF mice, miRNA 
sequencing was performed. Firstly, small RNAs (length less than 200 nt) were isolated 
from each murine cortical tissue, including miRNAs, which are between 17 and 25 nt 
of length. Secondly, two adaptors (total length around 130 nt, including indexes, used 
for differentiating each sample) were ligated to the 5’- and 3’- termini of small RNAs, 
respectively. Then the products were transcribed into cDNA. Since miRNAs were the 
analytical targets in this study, the cDNA fragments length between 140 and 160 bp 
represented miRNAs transcription results and were purified from all cDNA fragments. 
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Finally, all the samples were mixed together in equimolar amounts and loaded for next 
generation sequencing. 
2.1 Quality control of cDNA fragments for each sample 
Before mixing all the samples together, the quality of each sample had to be 
determined. In order to determine the content of cDNA fragments length between 140 
and 160 bp, an analysis which measured precise size and concentration of all dsDNA 
fragments was performed by using the Agilent Bioanalyzer, High Sensitivity DNA kit. 
The detection of fragments with 140-160 bp length implied that the quality of this 
sample was good. Figure 8 showed an exemplary analysis with cDNA for a 2-month-
old mouse. 
Fig. 8: Quality identification of cDNA fragments 
The x axis represents size of fragments; the y axis displays fluorescence absorption intensity. The 
first and last peaks (is green and purple) are the lower and upper marker peaks. The other peaks 
represent the cDNA fragments with different sizes, respectively. The blue line points out the location 
of fragments with size between 140 and 160 bp.  
The quality control was performed for all samples in this study, the results showed 
fragments of 140-160 bp length in all samples, therefore, the quality of all samples (2-, 
3- and 4-month-old mice) was good and could be used for miRNA sequencing. 
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2.2 Data analysis after miRNA sequencing 
In order to observe miRNAs expression level, sequencing was performed by using the 
NextSeq 500™ system of Illumina. The sequencing yielded a total of 3.5 Giga base 
pairs (Gbp) of raw data for all samples. Quality scores was used to check the 
probability of sequencing errors, Q30 represents an error rate of 0.1%, with an 
accuracy of 99.9%. It showed that 97.1% of data was identified to score higher than 
Q30, therefore, this data was considered to have good quality (Figure 9).  
Fig. 9: Quality identification of miRNA sequencing datasets 
The x axis represents Q scores; the y axis represents the yield of data (million base pairs). Green 
columns represent data with Q scores higher than 30. Blue columns indicat data with Q Scores 
lower than 30.  
2.2.1 Prediction of overall similarity and difference between each sample 
Galaxy Bioinformatics platform was used to analyze the data (https://usegalaxy.org/). 
The samples could be distinguished based on the unique indexes for each sample. In 
order to visualize genetic distance and relatedness between each sample, a principal 
component analysis (PCA) was performed by using EdgeR package. PCA is a 
statistical technique which can be used to reduce the dimensions of a dataset. The 
number of variables retained in a PCA was determined by a method of scree test 
(Cattell, 1966). The bar graph showed the proportion of variability explained per 
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principal component (Figure 10A). PCA plot often contains the first two components, 
as these describe the largest variability (Figure 10B).  
Fig. 10: Similarity prediction for each sample 
(A) Screen plot gives the proportion of all PCs analysed. The x axis represents 34 of PCs, the y 
axis represents proportion of variation, the PCs are ordered in a decreasing ratio. (B) PCA plot 
displays the statistical distance between each sample. The x axis represents PC1 resulted from 
scree plot, the y axis represents PC2 resulted from scree plot. Each dot represents individual 
sample among 2-, 3- and 4-month-old mice and is distinguished by different colors and shapes. 
The dots which represent 3- and 4-month-old PDGF mice were partially clustered. 
However, the dots which represent 2-month-old PDGF mice showed relatively more 
distance to the dots of 3-and 4-month-old PDGF mice. The results implied that 3- and 
4-month-old PDGF groups are similar to some extent. One 2-month-old PDGF mouse 
(ID No.714) was excluded from further analysis to avoid deviation, since it was too far 
from the other sample dots (not shown on the PCA plot). 
2.2.2 Differential expression of miRNAs in PDGF mice at different time points 
In order to observe the differential expression of miRNAs in PDGF mice, the 
comparison analysis was performed with the EdgeR package. 
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2.2.2.1 General assessment of miRNAs' differential expression between 2-
month-old mice and the other PDGF mice 
Based on the finding that dendritic spine loss was detectable at the age of 3 months 
but not at 2 months of age in PDGF mice (Bumenstock et al., 2017), we ask the 
question if miRNAs expression change in PDGF mice between 2- and 3-month of age. 
Thus, a comparative analysis between PDGF mice older than 2 months (3- and 4-
months old) and PDGF plus controls in 2-month-old was performed. The results 
revealed that 4 out of 1966 miRNAs (mir-184-3p, mir-182-5p, mir-34c-5p and mir-200b-
3p) were significantly different in 3- and 4-month-old PDGF mice compared to 2-month-
old mice (PDGF and controls) (FDR < 0.1, Figure 11A, 11B). 
 
 33 
Fig. 11: Comparative analysis between PDGF mice (3- and 4-month-old) and all 2-month-old 
mice.  
(A) 1966 miRNAs are identified in PDGF mice and the top 10 of miRNAs with small FDR value are 
shown. LogCPM, the log counts per million, is regarded as a parameter of assessing expression 
level for miRNAs. LogFC, the log fold change, represents difference between groups. Minus logFC 
means that miRNA is downregulated. FDR, the false discovery rate, is an adjust of p-value. miRNAs 
show significant difference when FDR < 0.1. (B) shows the fold changes of significantly altered 
miRNAs when compared 3- and 4-month-old PDGF to 2-month-old mice (PDGF and controls), 
FDR < 0.1. 
Comparing 3- and 4-month-old PDGF to 2-month-old mice (PDGF and controls), the 
expression of mir-182-5p was reduced at 2 months of age compared to 3 months, 
followed by an increase from 3 to 4 months of age. The expression of mir-184-3p was 
reduced at 2 months compared to 3 months, followed by an increase from 3 to 4 
months. The expression of mir-200-3p was ascending over time. The expression of 
mir-34c-5p was increased from 2 to 3-month, followed by a decrease from 3 to 4 
months of age. 
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2.2.2.2 Differential expression of miRNAs in PDGF mice between each group (2, 
3, 4 months) 
For a more detailed analysis of miRNAs changes at different ages, a comparative 
analysis of miRNAs expression between PDGF mice at the age of 2, 3 and 4 months 
was performed. 
2.2.2.2.1 Comparison between 3 and 2 months old PDGF mice 
In order to identify miRNAs changes between 2 to 3 months old PDGF mice, a 
comparative analysis was performed between these two groups. It demonstrated that 
7 miRNAs (mir-148a-3p, mir-34a-5p, mir-298-5p, mir-1298-5p, mir-676-3p, mir-132-5p 
and mir-1264-3p) showed significant difference in expression between 3- and 2- 
month-old PDGF mice (FDR < 0.1) (Figure 12). 
Fig. 12: Differential expression of miRNAs between 3- and 2-month-old PDGF mice  
The top 10 of 1966 identified miRNAs with the smallest FDR values are given. LogCPM, the log 
counts per million, is regarded as a parameter of assessing expression levels for miRNAs. LogFC, 
the log fold change, represents differences between groups. Minus logFC means that miRNA is 
downregulated. FDR, the false discovery rate, is an adjust of the p-value. miRNAs show significant 
difference when FDR < 0.1.  
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The results showed that mir-34a-5p and mir-132-5p were upregulated in 3-month-old 
PDGF mice, and mir-148a-3p, mir-298-5p, mir-1298-5p, mir-676-3p and mir-1264-3p 
were downregulated in 3-month-old PDGF mice compared to 3-month-old PDGF mice. 
2.2.2.2.2 Comparison between 4 and 3 months old PDGF mice 
In order to observe miRNAs changes in 4-month-old PDGF mice compared to 3-
month-old ones, a miRNAs differential expression analysis was performed between 
these two groups. We observed that only mir-182-5p was upregulated in 4-month-old 
PDGF mice compared to 3-month-old PDGF mice (FDR < 0.1) (Figure 13). 
Fig. 13: Differential expression of miRNAs between 4- and 3-month-old PDGF mice  
The top 10 of 1966 identified miRNAs with the smallest FDR values are given. LogCPM is the log 
counts per million, which is regarded as a parameter of assessing expression levels for miRNAs. 
LogFC, the log fold change, represents difference between groups. Minus logFC means that 
miRNA is downregulated. FDR, the false discovery rate, is an adjust of the p-value. miRNAs show 
significant difference when FDR < 0.1.  
The results demonstrated that the miRNAs expression was barely different in 4-month-
old compared to 3-month-old PDGF mice. 
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2.2.2.2.3 Comparison between 4 and 2 months old PDGF mice 
Aim to double check the comparative results above, a comparative analysis was 
performed between 4- and 2-months-old PDGF mice. It was shown that 10 of miRNAs 
were significantly changed, namely mir-182-5p, mir-183-5p, mir-10b-5p, mir-132-3p, 
mir-1298-5p, mir-132-5p, mir-7a-5p, mir-298-5p, mir-770-5p and mir-34c-5p (FDR < 
0.1) (Figure 14). 
Fig. 14: Differential expression of miRNAs between 4- and 2-month-old PDGF mice  
The top 10 of 1966 identified miRNAs with the smallest FDR values are given. LogCPM is the log 
counts per million, which is regarded as a parameter of assessing expression level for miRNAs. 
LogFC, the log fold change, represents difference between groups. Minus logFC means that 
miRNA is downregulated. FDR, the false discovery rate, is an adjust of p-value. miRNAs show 
significant difference when FDR < 0.1. 
Mir-182-5p, mir-183-5p, mir-132-3p and mir-132-5p were increased in 4-month-old 
compared to 2-month-old PDGF mice, and mir-10b-5p, mir-1298-5p, mir-7a-5p, mir-
298-5p, mir-770-5p and mir-34c-5p were decreased in 4-onth-old compared to 2-
months-old PDGF mice. The number of significantly changed miRNAs in the 
comparative analysis between 4 and 2 months old PDGF mice was more than in the 
comparative analysis between 3 and 2 (or 4 and 3) months old PDGF mice. Obviously 
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some slow but continuous miRNAs changes might occur that only become significant 
at 4 months of age. 
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DISCUSSION 
PD is a common neurodegenerative disease which involves a damage of synapses 
throughout disease progression. The mechanism of altered synaptic function in PD is 
not yet understood but there is evidence that this relates to altered miRNA expression. 
Indeed, many miRNAs have been found to be associated with synaptic plasticity. 
However, they are not only involved in normal synapse formation and function but also 
in pathophysiology of PD (Ye et al., 2016) were altered synaptic plasticity has been 
proposed. As dendritic spine loss was observed in the neocortex of 3-month-old PDGF 
mice (Blumenstock et al., 2017), the hypotheses was put forward that the expression 
of some miRNAs may change between 2 and 3 months of age. 
1. Differential expression of miRNAs between 2-month-old mice and the PDGF 
mice of 3 and 4 months of age 
In order to validate this hypothesis, a comparative analysis was performed between 2 
months PDGF plus control mice and 3- and 4-month-old PDGF mice. The results 
revealed that mir-184-3p, mir-182-5p, mir-34c-5p and mir-200b-3p were differentially 
expressed, which implied that these 4 miRNAs might mediate the dendritic loss in 
young PDGF mice.  
 
The expression of mir-184-3p was reduced comparing 2 to 3 months old mice, followed 
by an increase comparing 3 to 4 months old mice. There is some evidence that mir-
184 is involved in cognition and memory. Interestingly, changes in mir-184 expression 
have already been reported in neurodegenerative diseases that affect cognition. An in 
vivo study demonstrated mir-184 to be significantly downregulated in the hippocampus 
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of late-stage of AD, and it was verified that mir-184 was able to target NR4A2, which 
is found to be mediated cognition and long-term memory (Annese et al., 2018). 
  
The expression of mir-182-5p was reduced comparing 2 to 3 months old mice, followed 
by an increase comparing 3 to 4 months old mice. Only a small number of studies on 
mir-182-5p associate this miRNA with memory. Actin (the major component of dendritic 
spines and is related to synaptic plasticity) and memory consolidation was regulated 
by mir-182-5p in male rat model (Fischer et al., 2004; Rex et al., 2010; Griggs et al., 
2013). As synaptic plasticity is the cellular basis of memory, mir-182-5p was predicted 
to play a role in synaptic plasticity. The changes of mir-182-5p in PDGF mice was 
different from Griggs’ findings, which might be due to the difference of the animal 
species and requires the furthermore studies. 
 
The expression of mir-34c-5p was increased comparing 2 to 3-month-old mice, 
followed by a decrease comparing 3 to 4 months old mice. The mir-34 family miRNA 
is well studied in mammals. Mir-34b/c is mainly expressed in brain and lung tissue 
(Bommer et al., 2007). Mir-34 family members were considered to mediate tumor-
suppressive effects (Li et al., 2009; Liu et al., 2011; Yamamura et al., 2012). Recently, 
there is some evidence that mir-34 may also be relevant for neurons. Downregulation 
of mir-34b/c has been found both at motor and pre-motor stages of PD patients’ 
amygdala, frontal cortex, SN and cerebellum (Minones-Moyano et al., 2011). Mir-34 
was found to be involved in neuronal differentiation in a drosophila model. In zebrafish, 
the silencing of mir-34 caused to the defect of neuronal development (Soni et al. 2013). 
Moreover, some in vivo evidence also confirmed that mir-34 mediate memory function. 
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A study demonstrated that the inhibition of mir-34 cause to an impaired reference 
memory in the Morris water maze (Malmevik et al., 2016).  
 
The expression of mir-200b-3p was ascending over time in PDGF mice. Lately, the 
mir-200 family (including mir-200a, -200b, -200c, -141 and -429) has been found to be 
involved in neurodegenerative diseases. Increasing evidence has indicated that the 
miRNAs regulate proliferation, differentiation and apoptosis of neurons (Pandey et al., 
2015; Trümbach et al., 2015). There are no reports of the role of mir-200 family in PD. 
But in Huntington’s disease (HD), which is another neurodegenerative disease, an 
upregulation of mir-200a and mir-200c have been observed in the cortex and striatum 
of young HD mice. It was confirmed that the changes of mir-200a and mir-200c 
expression may affect neuronal plasticity and survival (Jin et al., 2012). Jin’s finding 
implied that the mir-200 family might participate in neurodegenerative disease. The 
present study is the first one showing that this miRNA might also be relevant in PD. 
 
2. Differential expression of miRNAs in PDGF mice between each group (2, 3, 4 
months) 
In order to get more insights on miRNAs’ expression changes in PDGF mice at different 
ages, a comparative analysis between each PDGF group (2, 3 and 4 months of age) 
was performed. Besides mir-182-5p and mir-34c-5p changes similar to the results in 
the general assessment of miRNAs’ differential expression, there were further 12 
miRNAs that also showed significant changes, namely mir-148a-3p, mir-34a-5p, mir-
298-5p, mir-1298-5p, mir-676-3p, mir-132-5p, mir-132-3p, mir-1264-3p, mir-183-5p, 
mir-10b-5p, mir-7a-5p and mir-770-5p. Among them, mir-148, mir-298, mir-1298, mir-
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676, mir-1264, mir-183, mir-10 and mir-770 in neurodegenerative disorders are not 
known up to now. In contrast, the roles of mir-132 and mir-7 are well described. 
 
The expression of mir-132 is known to be a critical factor in the development, 
maturation and function of neurons, and the dysregulation of this miRNA is associated 
with several neurodegenerative disorders (Wanet et al., 2012). The downregulation of 
mir-132 was found in AD patients. Mir-132 was reduced in the hippocampus, medial 
frontal gyrus, temporal and frontal cortex starting from the Braak stage III (Lau et al., 
2010). This miRNA has also been identified to play an important role in the processing 
of synapse plasticity (Ye et al., 2016). However, the role of mir-132 in PD’s 
pathogenesis is controversial: downregulation of mir-132 was observed in cortex and 
brainstem in 12-month-old (Thy1)-human -syn (A30P)-transgenic mice (Gillardon et 
al., 2008). Whereas upregulation of mir-132 was identified in mesencephalon of a PD 
rat model (which is named Berlin-Druckrey IV (BD-IV) rats) at the age of 25 days 
(Lungu et al., 2013). Significant increase in the level of mir-132 was identified in PD 
patients (Alieva et al., 2015). The reasons for these conflicting results on mir-132 in 
PD are unknown and require further studies. 
 
Mir-7 is regarded as a critical miRNA which participates in PD pathogenesis. An in vitro 
study reported that mir-7 reduces neurotoxicity and apoptotic nerve cell death caused 
by -syn overexpression (Junn et al., 2009). Mir-7 was found to inhibit both -syn 
aggregation and inflammasome activation. Moreover, it was found to restore impaired 
adult neurogenesis in the subventricular zone (Fan et al., 2016). The expression of 
mir-7 was shown to be decreased in young PDGF mice, which is consistent with Junn 
and Fan’s findings. Interestingly, mir-7 was also found to prevent cell death (Kong et 
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al., 2009; Li et al., 2016). These results suggest that mir-7 might play an important role 
in PD.  
 
In this study, more than 10 miRNAs in young PDGF mice were identified known to be 
involved in synaptic plasticity, however, the causal relationship between these miRNAs 
and synaptic dysfunction remain unclear. Here functional studies are needed analysis. 
Overexpressing, knockdown or knockout of these miRNAs in animal models of PD 
might help to understand if these miRNA’s indeed affect synaptic plasticity. In 2011, 
Luikart downregulated mir-132 via stereotactic injections of a mir-132 sponge (bearing 
perfect binding sites for mir-132) in dentate gyrus to observe the expression of 
interleukin 6 (IL-6) in the granular neuronal layer of the adult mice hippocampus 
(Luikart et al., 2011). A mir-182 knockout mouse has been recently generated for 
studying the role of this miRNA in the retina (Jin et al., 2009), which might be useful in 
further studies in a PD related context. 
 
In conclusion, we identified that more than 10 miRNAs that were significantly changed 
in young PDGF mice at an age when dendritic spine loss occurs, especially mir-184-
3p, mir-182-5p, mir-34c-5p, mir-200b-3p, mir-132-5p and mir-7a-5p. This observation 
implies that these miRNAs might play an important role in cognitive changes that can 
be observed in about 80% of PD patients throughout the progression of the disease. 
Nevertheless, there were controversy in the expression and role of mir-132-5p, which 
have to be studied furthermore. In addition, the verification of miRNAs expression level 
by qPCR, the analysis of miRNAs potential downstream target genes and the miRNA’s 
function analysis will need to be done in future studies. However, the present study 
establishes for the first time a list of miRNAs alterations in a mouse model of PD that 
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coincides with the loss of dendritic spines. It provides important insights how miRNA 
might affect synaptic function in the cerebral cortex in the context of a-synuclein 
aggregation and suggests for further investigations aimed at better understanding the 
molecular mechanisms in PD. 
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